Natera Showcases Most Recent ProsperaTM Data at WTC 2025; Features 16 Abstracts with Five Oral Presentations
Natera's Prospera Test Shines at 2025 World Transplant Congress
At the recent 2025 World Transplant Congress, Natera, a global leader in cell-free DNA and genetic testing, showcased the impressive performance of its Prospera test in solid organ transplantation. The test, which focuses on organ health, particularly in kidney, heart, and lung transplants, presented a series of findings that affirm its high precision and reliability.
The Trifecta series of studies demonstrated Prospera's robust cross-organ utility, with three oral presentations highlighting its ability to detect allograft rejection across kidney, heart, and lung transplants. The PEDAL clinical trial, a prospective multi-center study on kidney transplant recipients, showed that Prospera Kidney can accurately predict long-term clinical outcomes after rejection episodes, providing crucial prognostic information to guide post-rejection treatment decisions. This study was recently published in the American Journal of Transplantation.
For heart transplantation, data including Prospera Heart combined with the Donor Quantity Score (DQS) showed strong performance for allograft rejection detection, also published recently in American Journal of Transplantation. An oral presentation detailed Prospera Kidney’s utility in monitoring chronic antibody-mediated rejection treatment using anti-CD38 monoclonal antibody therapy, with findings published in Kidney International Reports this month.
In summary, the 2025 presentations and publications affirmed that Prospera, through non-invasive donor-derived cell-free DNA (dd-cfDNA) measurement, provides high precision and reliability in monitoring and prognosticating allograft health, enabling more informed clinical decisions in kidney, heart, and lung transplant management.
These datasets represent some of the most comprehensive evidence to date supporting Prospera’s clinical utility across multiple solid organ transplants. Katelynn S. Madill-Thomsen, Ph.D. defined relationships among tests for Heart Transplant Antibody-Mediated Rejection, and also defined the hierarchy of relationships among tests for Kidney Transplant Antibody-Mediated Rejection. Ziad S. Zaky, M.D. used unsupervised Machine Learning with Dynamic Time Warping to help understand Longitudinal dd-cfDNA Trajectories in Kidney Transplant Patients. Wai-Choong Lye, M.D. presented on the use of Anti-CD38 Monoclonal Antibody Daratumumab for the Treatment of Chronic Active-Antibody Mediated Kidney Allograft Rejection. Katherine Vandervest, M.D. presented on 'Baseline Lung Allograft Dysfunction' and its association with different Cell-Free DNA dynamics after lung transplantation.
Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. Forward-looking statements in this press release are subject to known and unknown risks and uncertainties that may cause actual results to differ materially.
Navchetan Kaur, Ph.D. presented on the Trajectory of dd-cfDNA Levels in Patients Undergoing Repeat Kidney Transplantation, and Eileen Hsich, M.D. presented on Donor-Derived Cell-Free DNA and its lack of association with White Blood Cell Count in Heart Transplant Recipients, further adding to the body of knowledge supporting Prospera's clinical utility.
- The Prospera test, showcased at the 2025 World Transplant Congress, is a highly precise and reliable tool for monitoring organ health, especially in kidney, heart, and lung transplants.
- The Trifecta series of studies demonstrated Prospera's cross-organ utility, revealing its ability to detect allograft rejection across different organs, including kidney, heart, and lung transplants.
- The PEDAL clinical trial, focusing on kidney transplant recipients, showed that Prospera Kidney can accurately predict long-term clinical outcomes after rejection episodes, providing essential prognostic information for post-rejection treatment decisions.
- The comprehensive datasets from various studies and clinical trials support Prospera’s clinical utility in managing multiple solid organ transplants, including kidney, heart, and lung transplants, making it a crucial tool in health and wellness in the medical-conditions and chronic-diseases fields, specifically chronic kidney disease.
